$AXON
AXON ENTERPRISE, INC.

2024 Q2 Form 10-Q Financial Statement

#000106918324000032 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $504.1M $460.7M $343.0M
YoY Change 34.57% 34.31% 33.78%
Cost Of Revenue $200.4M $200.7M $138.9M
YoY Change 40.62% 44.44% 37.99%
Gross Profit $303.7M $260.0M $204.1M
YoY Change 30.85% 27.41% 31.05%
Gross Profit Margin 60.25% 56.44% 59.5%
Selling, General & Admin $169.4M $152.7M $116.6M
YoY Change 41.28% 30.97% 29.33%
% of Gross Profit 55.78% 58.71% 57.11%
Research & Development $101.4M $91.10M $70.93M
YoY Change 41.0% 28.44% 46.49%
% of Gross Profit 33.4% 35.03% 34.75%
Depreciation & Amortization $13.00M $11.56M $6.689M
YoY Change 73.8% 72.88% 16.23%
% of Gross Profit 4.28% 4.45% 3.28%
Operating Expenses $270.9M $243.8M $187.5M
YoY Change 41.17% 30.01% 35.33%
Operating Profit $32.87M $16.28M $16.61M
YoY Change -18.34% -1.97% -3.41%
Interest Expense $9.782M $10.37M $25.28M
YoY Change -118.68% -58.96% -54.29%
% of Operating Profit 29.76% 63.72% 152.19%
Other Income/Expense, Net $7.934M $139.1M $15.61M
YoY Change -112.79% 790.88%
Pretax Income $50.59M $165.7M $41.88M
YoY Change -517.79% 295.66% -42.22%
Income Tax $9.793M $32.50M -$3.255M
% Of Pretax Income 19.36% 19.61% -7.77%
Net Earnings $40.80M $133.2M $45.14M
YoY Change 228.48% 195.13% -17.74%
Net Earnings / Revenue 8.09% 28.91% 13.16%
Basic Earnings Per Share $0.54 $1.77 $0.62
Diluted Earnings Per Share $0.53 $1.73 $0.61
COMMON SHARES
Basic Shares Outstanding 75.47M 75.30M 72.86M
Diluted Shares Outstanding 77.55M 77.13M 73.88M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $674.0M $503.6M $318.2M
YoY Change 25.05% 58.25% -28.32%
Cash & Equivalents $566.5M $403.9M $263.4M
Short-Term Investments $107.6M $99.72M $54.81M
Other Short-Term Assets $122.0M $123.7M $142.3M
YoY Change 20.14% -13.1% 111.76%
Inventory $277.8M $271.3M $220.3M
Prepaid Expenses
Receivables $729.5M $742.9M $596.8M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.206B $2.202B $2.053B
YoY Change 4.41% 7.26% 79.1%
LONG-TERM ASSETS
Property, Plant & Equipment $215.3M $209.2M $172.7M
YoY Change 20.23% 21.13% 15.5%
Goodwill $307.8M $250.7M $44.98M
YoY Change 433.0% 457.33% 3.15%
Intangibles $85.57M $89.42M $11.27M
YoY Change 291.86% 693.43% -21.73%
Long-Term Investments $363.1M $295.5M $327.7M
YoY Change 45.77% -9.82% 90.31%
Other Assets $227.8M $212.5M $168.2M
YoY Change 28.04% 26.34% 71.6%
Total Long-Term Assets $1.537B $1.414B $955.3M
YoY Change 59.28% 48.07% 52.51%
TOTAL ASSETS
Total Short-Term Assets $2.206B $2.202B $2.053B
Total Long-Term Assets $1.537B $1.414B $955.3M
Total Assets $3.742B $3.616B $3.008B
YoY Change 21.61% 20.22% 69.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $104.1M $82.08M $65.99M
YoY Change 42.59% 24.38% 33.72%
Accrued Expenses $141.6M $127.4M $120.6M
YoY Change 19.85% 5.64% 73.7%
Deferred Revenue $485.9M $516.4M $408.1M
YoY Change 17.87% 26.55% 24.93%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $766.1M $757.5M $616.1M
YoY Change 22.53% 22.94% 30.9%
LONG-TERM LIABILITIES
Long-Term Debt $678.7M $677.9M $674.7M
YoY Change 0.47% 0.47%
Other Long-Term Liabilities $2.552M $3.078M $4.511M
YoY Change -10.24% -31.77% -1.79%
Total Long-Term Liabilities $2.552M $3.078M $4.511M
YoY Change -10.24% -31.77% -1.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $766.1M $757.5M $616.1M
Total Long-Term Liabilities $2.552M $3.078M $4.511M
Total Liabilities $1.814B $1.798B $1.605B
YoY Change 11.1% 12.04% 147.81%
SHAREHOLDERS EQUITY
Retained Earnings $605.3M $564.5M $302.2M
YoY Change 92.4% 86.81% 83.4%
Common Stock $1.494B $1.421B $1.262B
YoY Change 15.52% 12.6% 12.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $155.9M $155.9M $155.9M
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares $20.22M
Shareholders Equity $1.929B $1.818B $1.403B
YoY Change
Total Liabilities & Shareholders Equity $3.742B $3.616B $3.008B
YoY Change 21.61% 20.22% 69.71%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $40.80M $133.2M $45.14M
YoY Change 228.48% 195.13% -17.74%
Depreciation, Depletion And Amortization $13.00M $11.56M $6.689M
YoY Change 73.8% 72.88% 16.23%
Cash From Operating Activities $82.76M -$15.94M -$56.32M
YoY Change 94.02% -71.7% -228.11%
INVESTING ACTIVITIES
Capital Expenditures $11.32M $16.19M $8.513M
YoY Change -14.25% 90.23% -50.21%
Acquisitions $237.8M
YoY Change
Other Investing Activities $93.46M -$157.9M -$64.04M
YoY Change -44.08% 146.5% -1043.51%
Cash From Investing Activities $82.14M -$174.0M -$72.67M
YoY Change -46.64% 139.49% 602.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.185M -2.710M 37.99M
YoY Change -115.32% -107.13% -2703.84%
NET CHANGE
Cash From Operating Activities 82.76M -15.94M -56.32M
Cash From Investing Activities 82.14M -174.0M -72.67M
Cash From Financing Activities -2.185M -2.710M 37.99M
Net Change In Cash 162.7M -194.7M -90.23M
YoY Change -22.83% 115.75% -381.96%
FREE CASH FLOW
Cash From Operating Activities $82.76M -$15.94M -$56.32M
Capital Expenditures $11.32M $16.19M $8.513M
Free Cash Flow $71.45M -$32.13M -$64.84M
YoY Change 142.54% -50.44% -341.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001069183
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75301424
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75466171
CY2023Q1 axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
CY2023Q1 axon Equity Securities Without Readily Determinable Fair Value Gain On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities
CY2023Q1 axon Equity Securities Without Readily Determinable Fair Value Loss On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueLossOnSaleOfSecurities
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2023Q1 axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-16391
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Axon Enterprise, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-0741227
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
17800 North 85th Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85255
CY2024Q1 dei City Area Code
CityAreaCode
480
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
991-0797
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 Par Value
CY2024Q1 dei Trading Symbol
TradingSymbol
AXON
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75467220
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
403870000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
598545000
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
99720000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
77940000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
560186000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
644054000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2298000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2392000
CY2024Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
476764000
CY2023Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
417690000
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
266172000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
275779000
CY2024Q1 us-gaap Inventory Net
InventoryNet
271318000
CY2023Q4 us-gaap Inventory Net
InventoryNet
269855000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
123677000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
112786000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2201707000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2396649000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
209166000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
200533000
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
208861000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
229513000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
89419000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19539000
CY2024Q1 us-gaap Goodwill
Goodwill
308470000
CY2023Q4 us-gaap Goodwill
Goodwill
57945000
CY2024Q1 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
2397000
CY2023Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
2588000
CY2024Q1 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
88209000
CY2023Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
77710000
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
295497000
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
231730000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
212470000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
220638000
CY2024Q1 us-gaap Assets
Assets
3616196000
CY2023Q4 us-gaap Assets
Assets
3436845000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
82075000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
88326000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127415000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
188230000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
516404000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
491691000
CY2024Q1 axon Customer Deposit Current
CustomerDepositCurrent
21979000
CY2023Q4 axon Customer Deposit Current
CustomerDepositCurrent
21935000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9601000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9787000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
757474000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
799969000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
293878000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
281852000
CY2024Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
18610000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
18049000
CY2024Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
14700000
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
11342000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32546000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33550000
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
677895000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
677113000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3078000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2936000
CY2024Q1 us-gaap Liabilities
Liabilities
1798181000
CY2023Q4 us-gaap Liabilities
Liabilities
1824811000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75466171
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75301424
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1421080000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1347410000
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
20220227
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
20220227
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
564467000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
431249000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11586000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10679000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1818015000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1612034000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3616196000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3436845000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
460736000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200690000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
138941000
CY2024Q1 us-gaap Gross Profit
GrossProfit
260046000
CY2023Q1 us-gaap Gross Profit
GrossProfit
204102000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152669000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
116567000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91097000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70927000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
243766000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
187494000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
16280000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
16608000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10374000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9666000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139066000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15610000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
165720000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
41884000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32502000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3255000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
133218000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.77
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.73
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75355000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72638000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77132000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73880000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
133218000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-801000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1676000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-106000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
184000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
132311000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46999000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1612034000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-2710000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75115000
CY2024Q1 axon Adjustments To Additional Paid In Capital Replacement Awards Issued In Connection With Acquisitions
AdjustmentsToAdditionalPaidInCapitalReplacementAwardsIssuedInConnectionWithAcquisitions
1265000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
133218000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-907000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1818015000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1268491000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33650000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-34841000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54346000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34350000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1860000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1402995000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
133218000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
45139000
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
97419000
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
15570000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
75115000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34350000
CY2024Q1 axon Gain On Remeasurement Of Previously Held Minority Interest
GainOnRemeasurementOfPreviouslyHeldMinorityInterest
42292000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
20670000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-9660000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11564000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6689000
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-4990000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-3890000
CY2024Q1 axon Non Cash Lease Expense
NonCashLeaseExpense
1795000
CY2023Q1 axon Non Cash Lease Expense
NonCashLeaseExpense
1395000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
782000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
756000
CY2024Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
544000
CY2023Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
855000
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
461000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
1047000
CY2024Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
51132000
CY2023Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
50431000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
710000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15811000
CY2024Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-2000
CY2023Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
64348000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-84289000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37043000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
20743000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
50199000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15938000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56323000
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
241457000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
145124000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
330472000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81088000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16194000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8513000
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
125000
CY2024Q1 axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
9128000
CY2024Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
237771000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-174044000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72674000
CY2023Q1 axon Net Proceeds From Equity Offering
NetProceedsFromEquityOffering
33650000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
39181000
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2710000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
34841000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2710000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37990000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1978000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
779000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-194670000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90228000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
600670000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355552000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
406000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
265324000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
403870000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263414000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2130000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1910000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
406000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
265324000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1413000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
20936000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1406000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1130000
CY2023Q1 axon Receivables From Options Exercised
ReceivablesFromOptionsExercised
15165000
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
133218000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75355000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72638000
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1243000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1242000
CY2024Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
534000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77132000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73880000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.77
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.73
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5808000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7503000
CY2024Q1 axon Warranty Period After Purchase Of Product
WarrantyPeriodAfterPurchaseOfProduct
P1Y
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
7374000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
811000
CY2024Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2207000
CY2023Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
438000
CY2024Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1119000
CY2023Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
2928000
CY2024Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
6286000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3301000
CY2024Q1 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
8100000
CY2023Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
7600000
CY2024Q1 axon Debt Instrument Principal Amount Denomination For Fair Value Calculation
DebtInstrumentPrincipalAmountDenominationForFairValueCalculation
1000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
2100000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
2100000
CY2024Q1 axon Restricted Cash Including Prepaid Expenses And Other Assets
RestrictedCashIncludingPrepaidExpensesAndOtherAssets
2000000.0
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification of Prior Year Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.</p>
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
460736000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
460736000
CY2024Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
354381000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
810282000
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
186485000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
516404000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
293878000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
810282000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
491691000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
281852000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
773543000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
516404000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
293878000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
810282000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
491691000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
281852000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
773543000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
7000000000.0
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1054585000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9728000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
537000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1063776000
CY2024Q1 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
403870000
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
99720000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
560186000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
531500000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
531500000
CY2024Q1 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses
25200000
CY2024Q1 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Gross Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses
100000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1333022000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
158000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12641000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1320539000
CY2023Q4 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
598545000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
77940000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
644054000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
420400000
CY2023Q4 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses
138800000
CY2023Q4 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Gross Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses
300000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3966000
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
217000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
353000
CY2024Q1 axon Allowance For Doubtful Accounts Receivable Other
AllowanceForDoubtfulAccountsReceivableOther
-14000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3844000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2298000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2392000
CY2024Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1516000
CY2023Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1516000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
30000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
44000
CY2023Q4 us-gaap Off Balance Sheet Credit Loss Liability
OffBalanceSheetCreditLossLiability
14000
CY2024Q1 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3844000
CY2023Q4 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3966000
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
107121000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
104112000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
164197000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
165743000
CY2024Q1 us-gaap Inventory Net
InventoryNet
271318000
CY2023Q4 us-gaap Inventory Net
InventoryNet
269855000
CY2023Q4 us-gaap Goodwill
Goodwill
57945000
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
250653000
CY2024Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
231000
CY2024Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
103000
CY2024Q1 us-gaap Goodwill
Goodwill
308470000
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
110565000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22945000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
87620000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
42978000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25282000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17696000
CY2024Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1799000
CY2024Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1799000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1843000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1843000
CY2024Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
112364000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22945000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
89419000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
44821000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25282000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19539000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000.0
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
11520000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
12534000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
12336000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
11394000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
11283000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
11098000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7377000
CY2024Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
6286000
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
7374000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
17455000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
87620000
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
231730000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1654000
CY2024Q1 axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
9128000
CY2024Q1 axon Equity Securities Without Readily Determinable Fair Value Gain On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities
45162000
CY2024Q1 axon Equity Securities Without Readily Determinable Fair Value Loss On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueLossOnSaleOfSecurities
-2870000
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
75639000
CY2024Q1 axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
-63292000
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
295497000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1654000
CY2024Q1 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
42300000
axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
155081000
axon Equity Securities Without Readily Determinable Fair Value Gain On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities
57474000
axon Equity Securities Without Readily Determinable Fair Value Loss On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueLossOnSaleOfSecurities
-2870000
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
179529000
us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
84009000
axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
4838000
axon Equity Securities Without Readily Determinable Fair Value Sales
EquitySecuritiesWithoutReadilyDeterminableFairValueSales
14546000
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
295497000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35997000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
125636000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
22392000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
5784000
CY2024Q1 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
20944000
CY2023Q4 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
12197000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10415000
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
460736000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31381000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29862000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127415000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
188230000
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
208900000
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
26100000
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
26100000
CY2024Q1 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6500000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.196
CY2024Q1 axon Effective Income Tax Rate Reconciliation Estimate Before Discrete Adjustments
EffectiveIncomeTaxRateReconciliationEstimateBeforeDiscreteAdjustments
0.219
CY2024Q1 axon Effective Income Tax Rate Reconciliation Deduction Stockbased Compensation
EffectiveIncomeTaxRateReconciliationDeductionStockbasedCompensation
4100000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2024Q1 axon Adjusted Gross Margins
AdjustedGrossMargins
291327000
CY2023Q1 axon Adjusted Gross Margins
AdjustedGrossMargins
205422000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
75115000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34350000
CY2024Q1 axon Debt Instrument Covenant Consolidated Leverage Ratio
DebtInstrumentCovenantConsolidatedLeverageRatio
-0.15
CY2024Q1 axon Debt Instrument Covenant Consolidated Interest Coverage Ratio
DebtInstrumentCovenantConsolidatedInterestCoverageRatio
51.03
CY2024Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
2
CY2024Q1 axon Product Claims Self Insurance
ProductClaimsSelfInsurance
5000000.0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29595000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1320000
CY2024Q1 axon Amortization Of Acquired Technology Intangible Assets
AmortizationOfAcquiredTechnologyIntangibleAssets
1686000
CY2024Q1 us-gaap Gross Profit
GrossProfit
260046000
CY2023Q1 us-gaap Gross Profit
GrossProfit
204102000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152669000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
116567000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91097000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70927000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10374000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9666000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139066000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15610000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
165720000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
41884000
CY2024Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
3500000
CY2024Q1 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
42300000
CY2024Q1 us-gaap Goodwill
Goodwill
250700000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
72900000
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
8100000
CY2024Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P7Y6M

Files In Submission

Name View Source Status
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001069183-24-000032-index-headers.html Edgar Link pending
0001069183-24-000032-index.html Edgar Link pending
0001069183-24-000032.txt Edgar Link pending
0001069183-24-000032-xbrl.zip Edgar Link pending
axon-20240331.xsd Edgar Link pending
axon-20240331x10q.htm Edgar Link pending
axon-20240331xex31d1.htm Edgar Link pending
axon-20240331xex31d2.htm Edgar Link pending
axon-20240331xex32.htm Edgar Link pending
axon-20240331_def.xml Edgar Link unprocessable
axon-20240331_lab.xml Edgar Link unprocessable
axon-20240331_pre.xml Edgar Link unprocessable
axon-20240331x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
axon-20240331_cal.xml Edgar Link unprocessable